4.5 Article

Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro

Journal

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
Volume 1818, Issue 11, Pages 2502-2510

Publisher

ELSEVIER
DOI: 10.1016/j.bbamem.2012.05.019

Keywords

alpha-Synuclein; Parkinson's disease; Oligomers; Membrane permeabilisation; Lipid vesicle; Polyphenols

Funding

  1. Malta Council for Science and Technology [RI-2008-068]
  2. University of Malta [R09-31-309]
  3. Malta Government Scholarship Scheme
  4. Deutsche Forschungsgemeinschaft

Ask authors/readers for more resources

Cumulative evidence now suggests that the abnormal aggregation of the protein a-synuclein (alpha S) is a critical factor in triggering neurodegeneration in Parkinson's disease (PD). In particular, a fundamental pathogenetic mechanism appears to involve targeting of neuronal membranes by soluble oligomeric intermediates of alpha S, leading to their disruption or permeabilisation. Therefore, a model assay was developed in which fluorophore-loaded unilamellar vesicles were permeabilised by soluble oligomers, the latter formed by aggregation of human recombinant alpha S protein. The alpha S oligomers induced an impairment of membrane integrity similar to that of the pore-forming bacterial peptide gramicidin. The lipid vesicle permeabilisation assay was then utilised to screen 11 natural polyphenolic compounds, 8 synthetic N'-benzylidene-benzohydrazide compounds and black tea extract for protection against membrane damage by wild-type and mutant (A30P. A53T) synuclein aggregates. A select group of potent inhibitory compounds included apigenin, baicalein, morin, nordihydroguaiaretic acid, and black tea extract. Structure-activity analysis further suggests that a 5,7-dihydroxy-chromen-4-one moiety appears to be favourable for the inhibition reaction. In conclusion, we have identified a group of polyphenols that can effectively hinder membrane damage by alpha S aggregates. These may serve as a viable source of lead compounds for the development and design of novel therapeutic agents in PD. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available